In particular, in the three differential equations that underlie many current in-vivo HIV immune cell models, uninfected cells are produced at a constant rate λ, infected cells at a rate βxv (transmission process with rate parameter β), and virions at a rate ky, whereas δx, ay, and uv are, respectively, the rates at which uninfected cells, infected cells and virions are removed from the system (death processes): k/a represents the burst size. This basic model and its elaborations do not account for immune cell production limitations caused by accumulated genetic errors  and the loss of telomere function  that ultimately results in immune senescence . These factors can be modelled by assuming a finite reservoir of hematopoietic stem cells  represented by the variable z(t) that decreases steadily with time t. A simple elaboration to the basic model that accounts for this is:
The basic model [1,2] is the first three equations with constant λ and u. The additional reservoir equation implies a drawdown rate c per uninfected cell production unit λ that we now assume depends on the size of the stem-cell reservoir z(t) and the level x(t) of uninfected cells. We will also assume now that the virion clearance rate u depends on z(t). These dependencies can be phenomenologically described as follows. First, we expect λ (x, z) to be a decreasing function of x because production should increase when uninfected cell counts are low. Initially, for non-depleted values of z, there should be little effect on either the maximum rates λ0 or u0 until the reservoir z(t) approaches exhaustion, at which point λ (x, z) reduces to 0 and u(z) to its background rate γ u0 (0 < γ < 1 to account for the loss of macrophage activity in removing virions). The extent to which z must be reduced for these rates to be at half their maximum values depends on many factors. Simple forms appropriate to the resolution of the model are:
accounts for increasing production rates as the uninfected cell population drops.
This extended model, in addition to replicating the acute and chronic infection stages of a typical HIV infection profile, captures the senescing immune system state at the onset of full-blown AIDS (Fig. 1) . The parameters used in Figure 1 are illustrative, because considerable variability exists among individuals in the intensity of infection at different stages of infection and in the time from infection to the onset of full-blown AIDS; the latter, for example, is known to decrease with age, with estimates [7,8] indicating a mean of 14–15 years at approximately the age of 10 years to about 8 years at approximately the age of 50 years. This decrease is expected under the assumption of a continuously drawndown hematopoietic stem-cell reservoir, because the reservoir equation implies z(0) decreases with the individual's age at the start of infection. It is also expected that the progression rate to full-blown AIDS is increased by factors that draw down the reservoir, such as previous parasite loads, chronic disease, and co-infections .
The first three equations in the four equation model presented here are too simple to capture many subtle phenomena associated with the acute and chronic phases of HIV infection, such as the persistence of low levels of plasma virus during potent antiretroviral therapy or the accumulation of mutations in immune cells over time. Multicell-type models employing additional differential equations are needed to investigate such phenomena [4,9]. Despite numerous elaborations to acute/chronic phase models represented by the first three equations, however, a basic model that captures all three in-vivo phases of HIV/immune cell dynamics (acute, chronic, collapse) using a single set of relatively simple differential equations has yet to be proposed. The four equation model presented here fulfils this role, although it will also need to be elaborated when used to address questions regarding the most effective design of HAART regimens or issues relating to the emergence of strains resistant to such interventions [9–11]. In addition, the fourth equation stresses our need to investigate and characterize more fully the exhaustibility of an individual's immunological system, particularly with regard to assessing its state as a hematopoietic stem-cell reservoir as a result of changes in lymphatic organs and bone marrow structure with age and history of infections. Finally, if immune system senescence is caused by the kind of extractive process modelled here, the results presented in Figure 1c have a profound bearing on the appropriate time to start antiretroviral treatment in HIV-positive individuals, particularly in individuals with co-infections such as Mycobacterium tuberculosis.
This work was funded by a Grant from NIH. I would like to thank John Hargrove, Brian Williams, Travis Porco, Maria Sanchez, and Russell Vance for comments that have improved this Research Letter.
1. Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo
: limitations on estimates on intracellular delay and virus decay. Proc Natl Acad Sci USA 1995; 93:7247–7251.
2. Nowak MA, May RM. Virus dynamics: mathematical principles of immunology and virology
. Oxford, UK: Oxford University Press; 2000.
3. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42:432–437.
4. Galvani AP. The role of mutation accumulation in HIV progression. Proc Royal Soc B 2005; 272:1851–1858.
5. Harrington L. Does the reservoir for self-renewal stem from the ends? Oncogene 2004; 23:7283–7289.
6. Scadden DT. Stem cells and immune reconstitution in AIDS. Blood Rev 2003; 17:227–231.
7. Belanger F, Meyer L, Carré N, Coutellier A, Deveau C, The Seroco Study Group. Influence of age at infectivity on human immunodeficiency virus disease progression to different clinical endpoints: The SEROCO cohort (1988–1994). Int J Epidemiol 1997; 26:1340–1345.
8. Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci USA 2005; 102:9619–9624.
9. Kim H, Perelson AS. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Computat Biol 2006; 2:1232–1247, e135 DOI10.1371/journal.cpbi.0020135.
10. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997; 94:6971–6976.
© 2008 Lippincott Williams & Wilkins, Inc.
11. Ramkisson S. Modelling the interaction between human immunodeficiency virus, Mycobacterium tuberculosis
, and the human immune system, including the effects of drug therapy. MSc dissertation. School of Physics, University of KwaZulu-Natal: Kwa-Zulu, Natal, South Africa; February 2007.